Skip to main content
. Author manuscript; available in PMC: 2021 Feb 3.
Published in final edited form as: Mol Pharm. 2020 Jan 14;17(2):717–721. doi: 10.1021/acs.molpharmaceut.9b01167

Figure 2.

Figure 2.

Single-agent or combination drug and antibody nanoparticle delivery systems. Preparation of the TfR-targeted combination CPT/Herceptin nanoparticle (A), TfR-targeted CPT nanoparticle (B), and TfR-targeted Herceptin nanoparticle (C) formulations. w ~ 82 for 3.4 kDa PEG; x ~ 20 for material used in this study; y ~ 84 for 3.5 kDa PEG; z ~ 120 for 5 kDa PEG.